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A NOVEL CARDIAC PACING PARADIGM FOR ATRIAL FIBRILLATION 
AND HEART FAILURE PATIENTS 
 
GEORGE EMANUEL YANULIS 
 
ABSTRACT  
 
     It has been estimated that 4.6 million persons have heart failure, and 400,000 
to 700,000 new cases develop each year and the U.S. Hospital discharges for 
HF rose from 399,000 in 1979 to 1,099,000 in 2004 according to the National 
Hospital Discharge Survey. Atrial fibrillation is the most common sustained 
cardiac arrhythmia in the United States.  Recent studies have demonstrated that 
ventricular rate control is a viable treatment strategy for patients in atrial 
fibrillation. 
     In a number of cases, despite the electrical resynchronization of the ventricles 
using biventricular pacing (cardiac resynchronization therapy), heart failure 
patients in sinus rhythm do not respond to cardiac resynchronization therapy as 
with other heart failure patients. These non-responders may respond to our 
pacing paradigm which is the combined use of cardiac resynchronization therapy 
which is commonly designated as CRT and coupled pacing (CP) which will be 
referred to as CRT+CP.  
     Using a custom “Y”-lead adapter, an unmodified dual chamber clinical 
pacemaker can be used to achieve almost any combination of an experimental 
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stimulation paradigm.  And by using the asynchronous mode of a dual chamber 
pacemaker, the ventricles can be paced at rates sufficient to produce heart 
failure (180 to 240 beats per minute) which had been successfully accomplished 
as part of the research protocol in our coupled pacing paradigm studies. These 
specially designed Y connectors facilitated our coupled pacing and biventricular 
pacing paradigm studies, i.e. allowed us to induce AF and apply CP under 
experimental conditions. 
     My research on this novel pacing paradigm (CRT+CP) has shown that it 
slowed the contractile rate by half (116±16 cycles per minute vs. 259±15 cycles 
per minute). And CRT+CP as compared with CRT at a similar contractile rate 
(CRT-vagal stimulation at 103±14 cycles per minute) also dramatically increased 
both the diastolic period (48±6% vs. 27±3%, p=0.02) and the left ventricular 
ejection fraction (51±10% vs. 25±4%, p<0.001) as well. 
      This research has further demonstrated that the addition of a coupled paced 
beat significantly increased the left ventricular strain.  The addition of coupled 
pacing to biventricular pacing also improved the left ventricular ejection (51 ± 
10%) to that of sinus rhythm despite the continual acute atrial fibrillation. CP may 
be combined with biventricular pacing (CRT+CP) to slow the ventricular rate of 
mechanical contractions and further improve contractility to a greater extent than 
what has been observed by CRT alone in patients with dyssynchronized heart 
failure and atrial fibrillation. 
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CHAPTER I 
Introduction to Coupled Pacing (CP) and CP with CRT 
 
1.1 Overview 
     The 5-year mortality of patients newly diagnosed with chronic heart failure 
(CHF) is 50%, despite the best of medical efforts [1].  Approximately 15-30% of 
heart failure patients are in concurrent atrial fibrillation (AF) [1].  At least 25% of 
heart failure patients develop major left ventricular conduction abnormalities.  
Last year 200,000 patients in the USA alone receive defibrillators at a cost of 
over $20,000 per unit. Hospital cost per implantation is currently set at a cost of 
approximately $10,000 [1].  These numbers are growing at an annual rate of 15-
20%. As the U.S. population ages, the incidence and prevalence of CHF are 
expected to dramatically increase according to Gregg C. Fonarow, MD (Director 
of the Ahmanson-UCLA Cardiomyopathy Center). He also articulated that CHF is 
the primary diagnosis for 875,000 hospitalizations annually, and it is the most 
common diagnosis among hospitalized patients 65 years of age or older. 
Fonarow further articulated that CHF had been the primary cause of death in 
approximately 250 000 people per year in 2001 [2]. Hospital discharges for CHF 
increased from 399,000 in 1979 to 1,099,000 in 2004 an increase of 175% 
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(NHDS and NHLBI). The estimated direct and indirect cost of CHF in the United 
States for 2007 is $33.2 billion [1]. In 2001, $4.0 billion ($5912 per discharge) was 
paid to Medicare beneficiaries for CHF [1] .The prevalence and incidence of heart 
failure and hospital discharges associated with this disease demonstrates the 
need for several life-style changes in order to decrease the increasing trends in 
this cardiovascular disease entity [2]. 
1.2 Background 
     Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the 
United States [3]. By increasing ventricular rate, AF can cause a tachycardia-
mediated cardiomyopathy. Previous work [4] has shown that when sinus rhythm 
can not be restored, ventricular rate control is a viable treatment option.  For the 
last several years, our laboratory has been investigating the implementation of 
coupled pacing (CP) [5-8], a novel pacing paradigm, for controlling ventricular rate 
of mechanical contraction (VRMC). CP involves application of electrical stimuli to 
the ventricles after the effective refractory period.  VRMC reduction by CP is the 
result of blocked conduction of rapid supra-ventricular activations to the ventricles 
during AF. We propose a new pacing regimen which is a combined therapy of 
CRT and CP.  Rather than the CRT ending during episodes of AF, the new pacing 
regimen could be applied. Briefly, (CRT+CP) will be applied as follows:  the 1st 
stimuli will be applied to the left ventricle and the 2nd stimuli to the right ventricle 
simultaneously in the same manner as CRT is used clinically today. Thus, these 
first 2 stimulations will result in a more synchronized electrical activation and 
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subsequent contraction of both ventricles. We will then apply a 3rd premature 
paced beat to activate both ventricles electrically but not mechanically. This 3rd 
paced beat to CRT will 1) block rapid supra-ventricular activation of the ventricles 
during AF, causing the ventricles to contract at a slower rate and 2) provide 
positive inotropic support [9] in a similar manner as we found for CP [5-8]. 
Electrical activity in the heart is spontaneously generated by the SA node which is 
also designated as the physiological pacemaker. This electrical impulse is 
propagated throughout the right atrium, and through Bachman's Bundle to the left 
atrium, stimulating the myocardium of the atria to contract [10]. The conduction of 
the electrical impulse continues throughout the atria is seen on the ECG as the P 
wave. As the electrical activity is spreading throughout the atria, it travels via 
specialized pathways, known as internodal tracts, from the SA node to the AV 
node. This latter node functions as a critical delay in the conduction system  
     Biventricular pacing also known as cardiac resynchronization therapy (CRT) is 
for the most part an effective pacing therapy in restoring a more uniform electrical 
activation and contractile performance in heart failure (HF) patients who are in 
sinus rhythm but have ventricular conduction system disturbances [11]. The 
pacemakers which are used in CRT follow the NASPE designation of pacing 
codes.  Although CRT is effective in many HF patients with LBBB, CRT is not 
effective in some HF patients despite resynchronization (non-responders) even 
during sinus rhythm. CRT can only be effective if the ventricular rate is controlled 
during AF. If CP is added to CRT, this could be an effective means of rate control. 
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      Today’s cardiac pacemakers that perform CRT generally sense atrial activity 
and also track their rate.  After sensing atrial activation, the device paces both 
ventricles at a shortened atrioventricular interval in order to insure that the 
ventricles are activated more uniformly by the biventricular pacing. However, if the 
rate of atrial activation suddenly increases or the atria fibrillate (paroxysmal AF), 
these pacemakers automatically will end atrial tracking and mode shut off.  That 
is, when their upper atrial tracking rate is exceeded, the biventricular pacing is 
shut off. Therefore, the beneficial effect of CRT is lost until the episode of AF ends 
and CRT can resume. 
1.3 Research Aims 
     For the past 3 years, Dr. Wallick and I have been studying a novel pacing 
modality called coupled pacing (CP) which is designed to improve cardiac function 
during atrial fibrillation (AF) and heart failure [8,12,13].  This pacing therapy both 
slows the rate of ventricular contraction and increases contractility.  CP first 
senses the intrinsic electrical activation of the heart. Then a delayed stimulation 
coupled to this intrinsic activation is applied, resulting in a second electrical 
activation with minimal mechanical contraction. However, the secondary electrical 
activation causes the subsequent intrinsic activation to result in a stronger 
contraction.  
 The rationale for the use of the canine as the animal model for our cardiac 
pacing research study for the evaluation of the CRT and CRT and CRT+CP is 
based on the similar anatomical and physiological similarities which exist between 
the canine and human cardiovascular systems [14] The canine model is a well-
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established model for studying AF and HF [15] The dogs are large enough that 
pacemakers and their leads could be implanted.  Additionally, the dog has a 
similar heart rate to that of a human.  Another important reason for the use of 
dogs is the ability to monitor them in the conscious state.  Finally, dogs are robust 
experimental animals and this helps assure success for our proposed 
experiments. 
 
1.3.1 Experimental Paradigm for AF 
     Protocols for producing experimental heart failure by rapid ventricular pacing 
are well established [16,17]; however, for safety reasons, commonly used clinical 
pacemakers do not allow pacing rates that are sufficient to induce either heart 
failure (HF) or atrial fibrillation (AF). In chapter 2, the experimental protocol for 
establishing AF using standard dual chambered cardiac pacemakers [12] will be 
discussed. More specifically rapid ventricular pacing was achieved by modifying 
a single-chamber pacemaker. In this study [12], we describe the use of a dual-
chamber pacemaker and a custom “Y”-lead adapter (Figure 1), and we show 
how rapid pacing can be achieved without the need to modify the circuitry or 
programming of a standard clinical pacemaker. 
     In a similar manner, experimental atrial fibrillation has been previously 
induced by the use of rapid atrial pacing [12]. Because of the shorter refractory 
period of atrial tissue, the pacing rate needs to be very rapid (400 to 600 bpm) to 
induce AF. Although specially modified clinical pacemakers have been built for 
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the purpose of induction of chronic atrial fibrillation, the method described as 
follows facilitates AF induction without the need for pacemaker modification [12]. 
 
1.3.2 Coupled Pacing  
     In chapter 3, my studies [13] using sustained coupled pacing will be 
discussed. Coupled pacing has both a negative chronotropic effect (decreases 
the heart rate) and as a positive inotropic effect (increases the myocardial 
contractility). Our research to date has demonstrated that the addition of a 
coupled paced beat significantly increased left ejection fraction (LVEF), and the 
1st derivative of left ventricular pressure development (LVdP/dt), and the left 
ventricular strain [8,12,13] which improves overall myocardial performance in HF 
and AF patients. In Chapter 3, I will also discuss how the use of coupled pacing 
(CP) and how it dramatically reverses the effects of persistent atrial fibrillation on 
the left ventricle [8]. 
 
1.3.3 CRT + CP Pacing 
     In Chapter 4, I will discuss how the addition of coupled paced beat to 
biventricular pacing improved the left ventricular ejection at a level which is 
comparable to that of sinus rhythm despite the continual acute atrial fibrillation 
occurring. 
     This chapter will also discuss how CP may be combined with biventricular 
pacing (CRT+CP) to slow the ventricular rate of mechanical contractions and 
further improve contractility to a greater extent than what has been observed by 
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CRT alone in patients with dyssynchronized heart failure and atrial fibrillation 
[13]. And by controlling the time delay of the application of CP, one can balance 
the negative chronotropic vs. positive inotropic effects of this pacing therapy in a 
manner that provides the most judicious treatment for each patient.  With the 
development of modern sensing capabilities of these pacemaker devices, one 
could easily make appropriate adjustments for each patient.  
 
1.3.4 Simulation flow in the Great Cardiac Vein (GVC) 
     Finally in chapter 5, the development of a mechanical simulation of flow 
patterns in great cardiac vein (GCV) will be presented as well as future work 
related to the use of implantable pressure sensors will be presented These 
sensors would have to be 1) accurate, 2) small enough to fit on pacing leads, 3) 
require simple electronics to function, and 4) most importantly require little 
energy. 
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CHAPTER II 
Use of Conventional Pacemakers to Induce Atrial Fibrillation 
in Dogs 
 
2.1 Introduction 
     Protocols for producing experimental heart failure by rapid ventricular pacing 
are well established [1]; however, for safety reasons, commonly used clinical 
pacemakers do not allow pacing rates that are sufficient to induce either heart 
failure (HF) or atrial fibrillation (AF). In one previous study, rapid ventricular 
pacing was achieved by modifying a single-chamber pacemaker [2]. We had 
been able to show how rapid pacing can be achieved without the need to modify 
the circuitry or programming of a standard clinical pacemaker. 
     In a similar manner, experimental atrial fibrillation has been previously 
induced by the use of rapid atrial pacing [3-4]. Because of the shorter refractory 
period of atrial tissue, the pacing rate needs to be very rapid (400 to 600 bpm) to 
induce AF. Although specially modified clinical pacemakers have been built for 
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Figure 1: Photograph showing the custom adapter made for us (Oscor™, 
Inc, Palm Harbor, FL). 
 
the purpose of induction of chronic atrial fibrillation [3-5], the method described 
as follows facilitates AF induction without the need for pacemaker modification. 
2.2 Materials and Methods 
     Under sterile conditions, three dogs were chronically implanted with one 
endocardial lead in the right atrial appendage and another in the right ventricular 
apex through the right jugular vein. Leads were tunneled subcutaneously toward 
the interscapular region. Each lead was attached to a custom “Y” adapter (Figure 
1). The “Y” adapters were attached to both ports of two dual-chamber 
pacemakers (Figure 1). The two pacemakers were then subcutaneously 
positioned 3 to 4 inches apart so that they could be separately interrogated and  
 
 
 
programmed [6]. 
     Because both ports of the ventricular pacemaker were used to apply stimuli 
through one lead, the device did not have to be modified to obtain ventricular 
pacing rates that are sufficiently elevated to lead to tachycardia-induced heart 
failure [6].  
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Figure 2:  Schematic diagram showing the placement of the leads, 
adapters, and pacemakers. Note that each lead uses a custom 
adapter to use both the atrial and ventricular ports of each 
pacemaker to provide two pacing pulses from each pacemaker. 
 
 
     The atrial and 
ventricular 
pacemakers were 
programmed at 
separate times. In 
this study they 
were not activated 
at the same time. 
Using the 
asynchronous 
mode (DOO) of 
the dual chamber 
pacemaker, the 
ventricles can be 
paced at rates 
sufficient to produce heart failure (180 to 240 bpm). For example, if the pacing 
interval is set at twice the desired interval (500 ms) and the atrioventricular (AV) 
delay (250 ms) is set such that a pacing pulse from the ventricular port fires at 
exactly half this interval, the ventricles can be paced at shortened intervals (i.e. 
stimulation pulses from both ports) without having to modify the clinical 
pacemaker [3]. 
 14
     Similarly, by using the DOO mode of the dual chamber pacemaker, both 
outputs can be connected to the atrial lead through the new lead adapter, and 
experimental atrial fibrillation can be induced if given sufficient time for pacing. 
For example, if the rate is set just above the intrinsic sinus rate and the AV delay 
of the dual chamber pacemaker is set to be sufficiently short enough, the first 
stimuli from the atrial port will pace the atria. The interval between the 2 pulses 
was shortened so that only a portion of the atria could be re-excited by the 
second stimuli originating from the ventricular port of the atrial pacemaker. This 
latter pacing paradigm (two tightly coupled stimuli) frequently initiates acute AF 
rather than a rapid and sometimes sustained atrial tachycardia. 
2.3 Results 
     Because the atrial and ventricular ports of both pacemakers were alternately 
used to stimulate the heart, there could have been significant leakage current 
from one port into the other port when our custom “Y”-lead adapter is connected 
to both ports [6] Because pacemakers are not constant current devices, this 
alternating firing from both ports could possibly deplete the battery of these 
devices prematurely. We consulted the manufacturer of the pacemakers that we 
were using and was informed that the input impedance of these devices is 
extremely high (1 MΩ). Because the impedance of the pacemaker lead-heart 
interface was always less than 1 kΏ, (approximately 500 Ώ), the leakage current 
back into the device and away from the heart should be less than 1% with the 
use of the “Y” adapter as previously described. In all animals, we used bipolar 
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Figure 3: Schematic-timing diagram shows the effects of 
activating either atrial or ventricular pacemaker alone. (Panel 1) 
When the ventricular pacemaker is turned off (ODO) mode, sinus 
rhythm is present. The second panel depicts what one would 
expect if the ventricles are paced at 120 bpm through the atrial 
port (AOO) mode. (Panel 3) If the asynchronous mode (DOO) is 
used with an atrioventricular (AV) interval of 250 ms, one would 
expect the response to be something like this. (Panel 4) When 
the atrial pacemaker is turned off, or in the (ODO) mode, a 
hypothetic sinus rhythm is displayed (sinus rhythm, 600 ms). The 
fifth panel depicts what one would expect if the atria are paced at 
140 bpm through the atrial port (AOO) mode. (Panel 6) If the 
(DOO) mode is used with an AV interval of 100 ms, one would 
expect the response to be something like this. (SR = sinus 
rhythm; VP = ventricular pacemaker; AP = atrial pacemaker.) 
pacing for both leads. In addition, bench testing showed that the lead impedance 
from the atrial port changed minimally (decreased approximately 1%) when both 
ends of the “Y” adapter were connected to the ventricular port compared with the 
impedance when only one end of the “Y” adapter was connected to the 
ventricular port. Thus 
battery life should not 
be appreciably 
shortened because of 
current leakage into 
one port when the 
other port is applying 
a pacing pulse [3]. 
     The distal end of 
the atrial lead was 
always placed in the 
right atrial 
appendage. Other 
activation sites in the 
atria may result in AF 
more readily (e.g., 
the pulmonary veins). 
However this location 
for lead placement was chosen to better assure that the distal end of the lead 
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would not migrate into the right ventricle and induce ventricular tachycardia or 
fibrillation because of the short coupled pacing from the atrial-ventricular ports of 
the atrial pacemaker. Similarly the distal end of the ventricular lead was always 
placed into the apex of the right ventricle because of the stability of this location. 
After both endocardial leads were attached, lead impedances and pacing 
thresholds were evaluated. At 0.5 ms pulse duration, both the atrial and 
ventricular leads captured the heart at less than 1 volt. The impedance of each 
lead-tissue interface was less than 1,000 ohms 
       All pacing to the ventricles was applied through bipolar leads. Individual 
pulses were routinely initially set at 5 V, 0.5 ms. The atrial port (AOO) mode was 
used to pace the ventricles at a rate sufficiently fast enough to capture the 
ventricles (120 bpm = 500 ms). Once ventricular pacing was achieved, the mode 
of pacing was changed to the DOO mode, and the ventricular port was activated 
at a 250 ms delay (see Figure 3).  
     All pacing to the atria was applied through bipolar leads. Individual pulses 
were routinely initially set at 5 V, 0.5 ms. In one case; atrial pacing at this 
intensity resulted in some phrenic nerve stimulation. Therefore the voltage was 
decreased to 3 volts and atrial pacing was maintained, still resulting in induction 
of AF. Because pacing measurements were set when the dogs were conscious 
and each dog had a different autonomic tone resulting in quite different sinus 
rates, pacing measurement settings for each animal had to be individually set 
and in some cases adjusted. The atrial port (AOO) mode was used to pace the 
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Figure 4: Diagram representing 5-second tracings of the 
electrocardiogram (lead II) from a conscious dog. The first panel shows 
the animal in sinus rhythm (SR). The second panel shows a paced 
ventricular tachycardia which will eventually lead to heart failure (VT-
HF) if the ventricles were to be rapidly being paced at 240 bpm. The 
third panel shows that atrial fibrillation (AF) has been acutely induced in 
this same animal. The fourth panel shows that sustained AF was 
induced in four weeks of paired atrial pacing as evident by the continual 
atrial fibrillation for 4 additional weeks after the atrial pacemaker has 
been turned off. 
atria at a rate 
sufficiently fast 
enough to 
capture the atria 
(range, 140 to 
180 bpm). Once 
the atrial pacing 
was achieved, 
the mode of 
pacing was 
changed to the 
DOO mode, and 
the ventricular 
port was 
activated at an 
80 to 100 ms 
delay (see 
Figure 3). The classical work of Wijffels and coworkers [4] showed that there is 
electrical remodeling of the atria as AF is being produced (i.e. the atrial refractory 
period decreases and sometimes necessitates a shortening of the coupling 
interval).  
     Figure 4 contains four panels of electrocardiographic recordings from one dog 
during conscious testing. In the first panel, the dog is in sinus rhythm, because 
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both the ventricular and atrial pacemakers are off (or in the ODO mode). The 
second panel of the electrocardiographic recording (i.e. the ventricular 
tachycardia which will eventually lead to heart failure (VT-HF) demonstrates the 
dog being paced for 5 seconds at 240 bpm, because the ventricular pacemaker 
is programmed in the DOO mode. The lower tracking rate was set at 120 bpm 
(500 ms). In addition, the AV interval was set at 250 ms.  These settings resulted 
in a ventricular pacing rate of 240 bpm, or a pacing interval of 250 ms, with this 
adapter and the dual output ventricular pacemaker. Then the ventricular 
pacemaker was turned off (ODO) mode. In all three animals, the ventricular 
pacemaker was not left in the DOO mode for more than 5 to 10 minutes. The 
purpose here was to show how heart failure could be induced if the pacemaker 
had been left on. 
     The third panel illustrates how AF can be induced when the atrial pacemaker 
is programmed in the DOO mode [6]. In this particular case, the rate is set above 
sinus rate at 140 bpm to capture the atria. In addition, the AV interval is set at 
100 ms in this case (note the pacing artifacts in the tracing). The arrow shows 
two stimuli separated by 100 ms. Thus, the second paced beat from the 
ventricular port of this atrial pacemaker stimulates the atrial tissue when only a 
portion of the atrial tissue appears to be excitable, a condition which leads to AF. 
Both the pacing rate and the AV interval can be readily modified as the atria 
undergo electrical remodeling to perpetuate the AF. We periodically turned off 
the atrial pacemaker to evaluate whether the heart would spontaneously return to 
sinus rhythm. In this particular animal, after 2 weeks of pacing sinus rhythm 
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Figure 5: Tracings of the electrocardiogram (lead II), the right and left ventricular electrograms 
(RVE and LVE) and right atrial electrogram in the same anima. The animal was in persistent 
atrial fibrillation for 12 weeks after the atrial pacemaker had been turned off. 
returned within 20 minutes when the pacing was stopped. After 4 weeks of atrial 
pacing, the atrial pacemaker was turned off and sustained AF continued for 
another 4 weeks (bottom panel). Because of the more rapid pacing rates used 
and the increased pacing stimulus intensity, battery life had decreased by 
approximately 3 months. However, this is a small portion of the total battery life 
for a commercial pacemaker.  
     After 16 weeks of persistent AF (as the pacemaker had been turned off for 12 
weeks), the pacemakers from the previously described animal were explanted 
during an acute experiment. Figure 5 shows the tracing of the right atrial 
electrocardiograms as well as 2 ventricular electrocardiograms and lead II. Note 
the rapid erratic activity of the atria found in AF is still present (i.e., right atrial 
electrocardiograms). The ventricular cycle length is regular in this part of the 
experiment because we were pacing both ventricles at a cycle length of 400 ms. 
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2.4 Discussion 
     The major finding of this study [6] is the observation that using a custom “Y”-
lead adapter, an unmodified dual chamber clinical pacemaker can be used to 
achieve almost any combination of an experimental stimulation paradigm. 
     For more than 20 years it has been known that rapid ventricular pacing can 
result in ventricular dysfunction and eventual heart failure [1-2, and 7]. In these 
studies, the pacing interval was held constant for various prescribed times. The 
time needed to produce tachycardia-induced heart failure is for the most part a 
function of the average pacing rate [1 and 7] (i.e. the faster one paces the heart, 
the faster heart failure symptoms develop). However, the time needed to develop 
heart failure for a given pacing rate is variable from animal to animal and 
therefore, sometimes it is unpredictable. Furthermore, many investigators 
monitor cardiac functional measurements, such as ejection fraction and vary the 
time of pacing to produce a more uniform state of heart failure. In a recent study 
[7], the investigators found that pacing at a slower rate for a longer period of time 
resulted in a model of heart failure that was more stable after the pacing was 
stopped. The purpose of this study had been to show how (with the use of a 
custom “Y”-lead adapter) rapid ventricular pacing at almost any rate can readily 
be accomplished without modification of the pacemaker or the rapid depletion of 
its battery. With the ease of programming commercial pacemakers, pacing 
measurements can readily be modified to fit the goals of a variety of protocols. 
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     In the same manner, persistent AF can be induced by use of electrical rapid 
atrial stimulation [3-5]. These atria can be stimulated using either periodic bursts 
(i.e. when sinus rhythm is sensed) or using a very rapid but constant stimulus 
paradigm. Both of these methods required modification of clinical pacemakers 
and they greatly increased battery life consumption. Battery consumption is a 
function of the pacing rate, pulse amplitude, and duration, as well as whether or 
not the monitoring functions are turned on. In the representative animal 
previously described, the battery life of the atrial pacemaker was decreased by 3 
months, even though the atrial pacing was continued for only 1 month. With 
lower stimulus intensity in the pacing pulses, it might have been possible to 
somewhat extend battery life; however, that may have resulted in the need to 
pace the animal for a longer period. Increased battery life consumption is 
primarily due to the higher than normal pacing rate (compared to that which is 
used clinically) and increased intensity of pacing, rather than the current leakage 
into the other port of the pacemaker. Despite our higher consumption settings, 
commercial pacemakers have the capacity to provide these pacing paradigms 
many times longer than needed. 
     Although the induction of AF by rapid pacing results in electrical remodeling of 
the atrial tissue and a shortening of the effective refractory period of the atrial 
tissue [4], both the pacing rate and the AV interval of the dual chamber 
pacemaker are readily adjusted to assure that the stimuli from the ventricular port 
of this atrial pacemaker perpetuated the AF. All of our animals eventually 
developed persistent AF. We continually paced for 4 to 5 weeks to insure that the 
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animals did not revert back to sinus rhythm once the pacemaker was turned off. 
In addition to our electrocardiographic measurements, we never observed the 
normal mitral inflow patterns seen in sinus rhythm while performing our weekly 
echocardiograms when the atrial pacemaker had been turned off. 
     In prior studies, persistent AF occurred only after structural remodeling of the 
atria had occurred [3-4 and 8-10], a phenomenon that generally occurs long after 
electrical remodeling. Thus, pacing may have to be applied for several months. 
For some unknown reason, our three animals remained in persistent AF after a 
shorter period of pacing. Even if the process should take 3 to 4 months, the 
battery of a conventional dual pacemaker should be adequate for the induction 
process. In a prior study, a modified atrial pacemaker was left on continuously in 
ensure that sinus rhythm would not return [6]. This could be done using our 
technique [6]. 
Because clinical leads and pacemakers are rugged, readily implantable, 
and can provide pacing for extended periods of time, they are ideal for these 
types of experiments. Thus, our present study [6] shows how with the addition of 
a “Y”-custom lead adapter, an unaltered dual-chamber pacemaker, and some 
imagination, AF or heart failure can be induced in a large animal model when 
given sufficient time. 
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Chapter III 
 
Coupled Pacing Reverses the Effects of Atrial Fibrillation on the Left Ventricle 
 
3.1 Introduction 
 
     Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the 
United States [1].  By increasing ventricular rate, AF can cause a tachycardia-
mediated cardiomyopathy.  Recent studies have shown that when sinus rhythm 
can not be restored, ventricular rate control is a viable treatment option [2].  For 
the last several years, our laboratory has been investigating the implementation 
of coupled pacing (CP), a novel pacing paradigm, for controlling ventricular rate 
of mechanical contraction (VRMC).  CP involves application of electrical stimuli to 
the ventricles after the effective refractory period.  In previous studies [3-5], we 
reported that acute application of CP resulted in both a negative chronotropic 
(mechanical not electrical rate) and a positive inotropic response during acutely 
induced AF.  VRMC reduction by CP is the result of blocked conduction of rapid 
supra-ventricular activations to the ventricles during AF.  When CP slowed the 
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VRMC, stroke volume increased markedly as a result of moderate increases in 
left ventricular end diastolic volume and a decrease in end systolic volume.  In 
addition, the positive inotropic effects of CP (resulting from postextrasystolic 
potentiation) increased LVdP/dt and LV ejection fraction. The purpose of this 
study [6] was to determine if the hemodynamic benefits of sustained CP could be 
maintained in the setting of persistent AF. 
 
3.2 Methods 
 
3.2.1 Surgical Preparation 
     The experimental protocol was approved by the Animal Research Committee 
of the Cleveland Clinic. All animals used in this study received humane care in 
compliance with the “Guide for the Care and Use of Laboratory Animals” 
published by National Institutes of Health. The Cleveland Clinic’s Animal Care 
facility is accredited by the American Association for the Accreditation of 
Laboratory Animal Care.  Six mongrel dogs (20-30 kg) were included in this 
study.  
 
3.2.2 Conscious Testing 
     All animals were trained to lie on a couch on their left side for 
echocardiographic examination.  Echocardiographic data were acquired 
(Sequoia™, Seimens System with a 3MHz probe) at 1) baseline during sinus 
rhythm, 2) after persistent AF but just before the beginning of CP therapy and 3) 
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after 3-4 weeks of continual application of CP. LV end systolic and diastolic as 
well as left atrial (measured at end systole of LV) volumes were computed from 
standard apical views (2 and 4 chamber views) by using the Simpson biplane 
method. Left ventricular ejection fraction (LVEF) was calculated from these 
measurements [(EDV-ESV)/EDV]. Measurements from three cardiac cycles were 
averaged for all volumes and these mean values were expressed as a single 
value.  The surface ECG was recorded during conscious testing via a Dataq™ 
acquisition system.  Origin® plotting software was used to plot representative 
ECG traces and other results. 
 
3.2.3 Pacemaker Implantations and Pacing Protocols 
     Under sterile conditions, dogs were chronically implanted with 2 endocardial 
pacemaker leads, one placed in the right atrial appendage and the other in the 
right ventricular apex.  As previously described [7], two standard dual chamber 
pacemakers were used for each animal.  Each device used a custom Y lead 
adapter (Oscor™) in order to induce AF and to apply coupled pacing.  With a Y-
adapter, we connected the atrial pacemaker lead to both the atrial and ventricular 
ports of a dual chamber pacemaker. Similarly, the ventricular lead was 
connected to a second dual chamber pacemaker via a second Y-adapter.  The 
Y-adapter permitted us to use both the atrial and ventricular ports of a dual 
chamber pacemaker to either pace (DOO mode) the heart via one lead, or to 
sense the intrinsic electrical activation of the heart via the atrial port and then 
apply a paced beat via the ventricular port (DDD mode).  Both pacemakers were 
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implanted subcutaneously, positioned sufficiently far apart that they could be 
separately interrogated and programmed. 
     After animals had fully recovered from pacemaker implantation surgery, rapid 
right ventricular pacing was applied at a rate of 240 bpm using the DOO mode of 
the ventricular pacemaker. The lower tracking rate was set at 120 bpm and the 
AV interval was set at 250 ms, as previously described [7]. Ventricular pacing 
was continuous at 240 bpm for two weeks.  Rapid ventricular pacing promoted 
ventricular dysfunction and atrial fibrosis that accelerates the development of 
persistent AF [8]. 
 
3.2.4 Echocardiography 
     Cardiac function was assessed using echocardiographic imaging when the 
pacemakers were turn off.  When LVEF was reduced by approximately 20% from 
the baseline value during normal sinus rhythm, the ventricular pacemaker was 
programmed off (from DOO to ODO).  At this time, the atrial pacemaker was 
programmed in AOO mode to pace the atria at a rate approximately 20 bpm 
above sinus rate. The mode of the atrial pacemaker was then switched to DOO 
and the AV interval setting was adjusted to an interval sufficiently short that 
stimuli from the ventricular port would still capture atrial tissue.  This pacing 
paradigm eventually induces persistent AF [7].  The AV interval varied from 80 to 
120 ms, depending on the individual animal and its autonomic state.  Weekly 
ECG measurements were obtained in order to confirm that the atrial pacing 
continually fibrillated the atria.  During the induction of AF, echocardiographic 
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assessments of left ventricular function were continued until the ejection fraction 
was reduced by approximately 30% from baseline levels. Then the atrial 
pacemaker was turned off and the animals remained in atrial fibrillation.  
     Coupled pacing was initiated through the use of the ventricular pacemaker 
programmed in DDD mode once ventricular dysfunction had developed and 
persistent AF was established (after ventricular and then atrial pacing, 6-8 weeks 
total).  The lower tracking rate of ventricle pacemaker was set at 30 bpm and the 
upper tracking rate was set at 180 bpm.  As in our acute experiments, the 
individual coupling interval was adjusted for each animal. With the use of the 
DDD mode of the ventricular pacemaker, the AV interval was adjusted to alter 
the CP time delay to intervals ranging from 160-220 ms.  Time delay adjustments 
were made while monitoring LV contractions via echocardiography such that 
virtually no secondary contractions were observed [5]. 
     Analysis of variance was used to determine if any of echocardiographic 
measurements (LVEDV, LVESV, LVEF, and LAV) were significantly changed [6]. 
In addition, we measured the ventricular rate of mechanical contractions (VRMC) 
as previously described [5]. These continuous variables were expressed as 
means±SE.  Paired comparisons were made between these 3 periods, i.e., BL 
vs. AF, AF vs. CP and BL vs. CP (Fisher LSD).  A probability of < 0.05 was 
considered significant.  
3.3 Results 
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Figure 6: ECG tracings of one dog taken during the 3 periods of this study.  The top panel 
shows when the animal was in sinus rhythm. The number indicates the intrinsic electrical 
activations.  The middle panel show when the animal was in persistent AF.  The bottom panel 
shows coupled pacing. 
Figure 6 displays representative ECG tracings of one dog during the three 
phases of this study [6].  The top panel shows normal sinus rhythm prior to the 
induction of persistent AF.  The middle panel show persistent AF just prior to the 
application of CP.  The bottom panel shows that AF persisted even after CP had 
been applied for 4 weeks.  The numbers above each R wave indicate intrinsic 
electrical activations that resulted in mechanical contractions. The CP stimulus 
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Figure 7: The effects of persistent AF and sustained CP on left ventricular ejection fraction 
(LVEF) and left ventricular rate of mechanical contraction (VRMC).  The * indicates that 
persistent AF significantly changed both LVEF and VCR.  The # indicates that sustained CP 
significantly reversed these prior changes within 3-4 weeks back toward their pre-AF values.   
following each of the intrinsic activations in the bottom panel is indicated by the 
stimulus artifact.  
      Persistent AF significantly increased the average VRMC (Figure 6, baseline 
to AF, 103 ± 2.5bpm to 174.5 ± 14.5 contractions/min (C/m), p<0.001).  CP 
brought the average VRMC back to 95.8 ± 9.2 C/m, (p<0.001).  As shown in 
Figure 7, LVEF was quite sensitive to supraventricular tachycardia, decreasing 
from 52 ±2 to 32±4% (p<0.01) during persistent AF, and returning to 47±2% 
(p<0.01) during CP.   
     We observed significant tachycardia-mediated LV remodeling, resulting in 
both left atrial and left ventricular dilatation. All ventricular dimensions 
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significantly increased as a result of persistent AF. The LVEDV increased from 
62.3 ± 4.78 mL to 75.5 ± 6.65 mL (BL vs. AF, Figure 8, p<0.01).  Similarly, 
LVESV increased from 30.7 ± 2.57 mL to 51 ± 4.57 mL (p<0.001), and LAV 
increased from 20.2 ± 3.84 mL to 34.8 ± 4 mL (p<0.01) during persistent AF 
(Figure 8).       After sustained CP had been applied for 3-4 weeks, LV volumes 
were significantly reduced (AF vs. CP, Figure 8) and returned toward the values 
measured prior to the induction of persistent AF. The LVEDV decreased from 
75.5 ± 6.65 mL to 65 ± 3.22 mL (AF vs. CP, p<0.0.5)) and the LVESV decreased 
from 51 ± 4.57 mL to 34.5 ± 2.41 mL (p=0.001).  The reduction in LV volumes 
also resulted in a partial reduction of LAV towards baseline values, despite the 
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Figure 8: The effects of persistent AF and sustained CP on left ventricular volumes (LVEDV 
and LVESV) and left atrial volumes (LAV). The * indicates that persistent AF significantly 
increased LVEDV, LVESV and LAV. The # indicates that sustained CP significantly reversed 
the AF-induced increases in LVEDV and LVESV.  Although CP reduced LAV, this change did 
not reach statistical significance.
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continued presence of AF. That is, LAV decreased from 34.8 ± 4 mL to 27.7 ± 
2.6 mL (p>0.05).  
 
3.4 Discussion 
     The first major finding of this study [6] is that the effects of CP were sustained 
for 4 weeks.  Sustained CP dramatically reduced the ventricular rate of 
mechanical contraction (VRMC) and increased contractile performance (LVEF), 
in a manner similar to that previously observed during acute AF.  Second, the 
sustained effects of CP resulted in a decrease of left ventricular volumes (reverse 
remodeling) that had become dilated during the induction of persistent AF.  
Reverse remodeling results in decreased wall stress.  
     Normally when the ventricles are electrically activated, there will be 
corresponding subsequent mechanical contractions which in turn results in 
ejection of blood.  However, during rapid AF this is not always the case. 
Hemodynamic measurements from a prior acute experiment illustrate this point 
(Figure 9).  That is, the 13 electrical activations result in 9 contractions and these 
contractions in turn lead to 6 ejections of blood (see the left panel of Figure 9).  In 
contrast, the application of CP during AF changes this relationship (see right 
panel of Figure 9).  The application of CP results in the blockage of every other 
rapid supraventricular activation.  However, since a coupled beat (no subsequent 
contraction) followed each intrinsic electrical activation, the ventricular rate of 
electrical activation (VREA) remained approximately the same with the 
application of CP during AF as the rate of AF alone.  The positive inotropic effect 
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Figure 9:Hemodynamic tracings without CP (left panel) and then with CP (right panel) in a 
prior acute experiment. Marks above ECG electrocardiogram tracings illustrate VREA, right 
ventricular (RV) electrogram, 1st derivative of left ventricular pressure (dp/dt). Marks above the 
left ventricular (LV) pressure tracings illustrate VRMC, and marks above the aortic flow 
tracings illustrate VREJ 
of CP via postextrasystolic potentiation now resulted in each intrinsic activation to 
result in a subsequent contraction and then ejection of blood.  That is, there were 
12 VREAs,  6 VRMCs, and 6 ejections (note the marks above events). 
     In our prior work examining the effects of acute CP on acute AF [3], we found 
that the rate of ventricular rate of electrical activation (VREA) changed from 135 
to 226 to 225 activations / min from sinus to AF to CP.  However the ventricular 
rate of mechanical contraction (VRMC) changed from 135 to 197 to 112 
contractions / min.  Finally the ventricular rate of ejections (VREJ) changed from 
135 to 136 to 111 ejections / min. Note, that without the application of CP, the 
VRMC would not be one half of the VREAs, but they would have remained high. 
     In the present study [6], the cardiac responses to persistent AF and then to 
sustained CP were somewhat different than previously observed during acute 
AF. Our coupled pacing resulted in no change in the VREAs but there was a 
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change in VRMC that is similar to the prior pre-tachycardia rate despite the 
persistence of AF.   In the current study, under persistent AF and chronic CP, the 
VRMC changed from 103 to 175 to 96 contractions / min.  Note, the application 
of CP at a shortened delay resulted in no contractions both in our prior acute 
studies (3-4) and in this present study [6]. 
     In most cases, heart rate is defined in terms of VREA rather than VRMC. So 
what is the concern of VREA vs. VRMC? In both acute and chronic conditions of 
AF, CP reduces the VRMC but has little effect on VREA.  In an earlier study [3], 
the inotropic effect of CP via postextrasystolic potentiation now resulted in each 
intrinsic activation to result in a subsequent contraction and then ejection of 
blood.  That is, there were 12 VREAs, 6 VRMCs, and 6 ejections (note the marks 
above events). 
A number of laboratories have reported that both chronic supraventricular 
and ventricular tachycardia caused significant left ventricular dilation as well as a 
reduction in the ejection fraction in dogs [9-12].  These studies also showed that 
after the termination of this tachycardia, there was a rapid return of their ejection 
fraction.  However, there remained a residual dilatation in their left ventricular 
volumes that eventually started to return towards pre-tachycardia levels.  In 
contrast, our present study showed that the left ventricular volumes returned 
back to their pre-tachycardia levels during the same time course as the ejection 
fraction improved. Thus, the positive inotropic effect of our CP may be partially 
responsible for the reverse remodeling as well as its negative chronotropic effect 
as defined by the VRMC rather than the VREA.  This reduction of left ventricular 
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volumes induced by sustained CP reduces wall stress.   
     Heart rate, contractility and wall stress are all major determinants of 
myocardial oxygen consumption (MVO2, [13-15].  Increases in both heart rate, 
that is, VRMC and wall stress via ventricular volume dilation during persistent AF 
leads undoubtedly increases metabolic demand and oxygen consumption.  Our 
present results suggest that both the reduced VRMC and wall stress caused by 
persistent CP should reduce MVO2 and therefore counteract the effects of 
increased contractility [13] on MVO2 that are also the result of CP.  However, 
additional experiments are needed to validate these assumptions. 
     In our present study [6], the remodeling induced by ventricular pacing and 
persistent AF is the result of a uniform ventricular dysfunction, similar to that 
which occurs during dilated cardiomyopathy [16].  Bi-ventricular pacing has been 
shown to reverse the remodeling of the failing left ventricle [17].  Beta-adrenergic 
receptor antagonists (β-blockers) can also cause reverse remodeling [18].  Both 
β-blockers and CP result in slower VRMC, although via quite different means.  
Whereas β-blockers are negative inotropic agents, CP has a positive inotropic 
effect.  Prior studies [17-18] suggest that reverse remodeling occurs when the 
ventricle become more efficient.  This improvement of ventricular function 
occurred as a result of either a more synchronous contraction, or by a slower rate 
of contraction.  In both cases, the time course required for reverse remodeling 
was several months.  In contrast, the reverse remodeling caused by CP here 
appears to have occurred more rapidly.  The increased rate of reverse 
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remodeling may be due in part to the positive inotropic effects of CP in addition 
the reduced VRMC. 
In summary, sustained application of CP appears to reverse the LV 
dilation and functional impairment (LVEF) that resulted from LV dysfunction 
during persistent AF. Therefore, following additional studies CP should be 
considered as a means to achieve ventricular rate control and to improve cardiac 
function in many cases of persistent AF, particularly in the presence of non-
ischemic dysfunction. Finally, by adding this pacing paradigm to a 
pacemaker/defibrillator device, these stimuli could be applied safely.  
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Chapter IV 
An Improved Cardiac Resynchronization Therapy  
 
4.1 Introduction 
     Cardiac Resynchronization Therapy (CRT) has been shown to improve 
symptoms and survival in patients with drug-refractory symptomatic heart failure 
(HF) and conductive disturbances [1-8]. However, in AF patients, CRT can be 
efficiently delivered only if the ventricular rate is controlled. If rate can not be 
controlled, atrioventricular (AV) nodal ablation and implantation of a permanent 
ventricular pacemaker may be required [9-10]. Therefore, we propose to apply a 
supplemental stimulation to the right ventricle, coupled pacing (CP), in addition to 
the standard CRT when AF occurs. For the past four years, our laboratory has 
been studying the potential application of this CP for the treatment of AF when 
there are no ventricular conductive problems [11-13]. In these prior cases, the 
intrinsic electrical activation of the ventricles which initiated the contraction was 
sensed and then an electrical stimulation (CP) was applied after the ventricular 
refractory period but prior to the time that the ventricles were capable of 
contracting again.  CP activated the ventricles electrically resulting in retrograde 
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activation of the AV node which in turn prevented rapid supra-ventricular 
activation of the heart during AF.  Thus, CP slowed the ventricular rate of 
mechanical contraction (VRMC) and increased LV filling.  In addition, this CP 
beat increases contractility via elevated intracellular calcium levels [14]. Based 
on these prior works, we hypothesized that CP may be combined with 
biventricular pacing (CRT+CP) to slow the VRMC and further improve 
contractility to a greater extent than what has been observed by CRT alone in 
patients with dyssynchronized HF and AF.   
 
4.2 Methods 
     The experimental protocol was approved by the Animal Research Committee 
of the Cleveland Clinic. All animals used in this study received humane care in 
compliance with the “Guide for the Care and Use of Laboratory Animals” 
published by National Institutes of Health. The Cleveland Clinic’s Animal Care 
facility is accredited by the American Association for the Accreditation of 
Laboratory Animal Care. 
     The dogs (n=6, body weight 22-29 kg) were initially anesthetized with 
thiopental 25 mg/Kg IV and maintained with 1-2% isoflurane vaporized in 
oxygen-enriched air during positive pressure ventilation.  A mid-sternotomy was 
performed and the heart was placed in a pericardial cradle. A custom 
quadrapolar plate electrode was sutured to the right atrium and was connected to 
a Grass stimulator.  
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4.2.1 Pacing protocol 
     Rapid right atrial pacing (20 Hz, 1 ms, 3-5 V) was used to induce and to 
maintain a rapid but continual acute AF after baseline measurements were 
obtained in sinus rhythm.  A second quadrapolar plate electrode was sutured on 
the right ventricular (RV) apex and was connected to the first channel of a Bloom 
stimulator. A third quadrapolar plate electrode was sutured on the lateral wall of 
the LV for CRT delivery and connected to the 2nd channel of our Bloom 
stimulator. The remaining 2 poles of these 3 quadrapolar electrodes were 
connected to our recording system to record their corresponding electrograms.  
Finally, a bipolar electrode was sutured on the inferior vena cava-left atrial 
epicardial fat pad of 3 animals to stimulate the parasympathetic nerve that 
innervates the AV node to slow A-V nodal conduction [15]. This nerve stimulation 
allowed us to apply the CRT at a rate to be similar as the response during AF 
and CRT+CP. 
     First, we obtained baseline measurements during sinus rhythm (step 1).  Next 
we simulated the effects of AF and left bundle branch block (LBBB) with 5 
minutes of rapid RV pacing and acute AF via rapid atrial pacing (step 2).  During 
AF, the rate of RV pacing (2 ms, 2-4 mA) was increased to a rate sufficient to 
prevent intrinsic ventricular activation over the AV node.  This pacing paradigm 
reduced ejection fraction to less than 35%.  This mode of pacing resulted in LV 
dysfunction [16] and dyssynchrony [17].  Then, we applied a rapid biventricular 
pacing for 5 min such that the CRT rate was sufficient to pace both ventricles 
directly (Step 3) without supraventricular activation. The pacing paradigm here 
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Figure 10: Illustrates a schematic diagram indicating
the sites of electrical stimulation applied to the heart during
the various stages of this study.
would be somewhat analogous to when a pacemaker would pace the ventricles 
rapidly by continually tracking atrial activity.  Clinically, the biventricular 
pacemakers that are in an 
atrial tracking mode will 
normally mode switch when 
atrial rate reaches a 
prescribed limit, that is, atrial 
tracking limit.  As long as AF 
persists, effective CRT will 
not be applied.  
     Next, we applied CRT 
(step 4) during acute AF at 
rate close to sinus rate 
because of the addition of 
the CP.  CRT+CP, which 
consisted of simultaneous 
biventricular pacing (2 ms, 
2-4 mA, both channels of 
the Bloom stimulator) of both ventricles was followed by an additional stimulation 
or CP (2 ms, 2-4 mA, 1st channel of the Bloom stimulator) applied only to the RV 
lead after the RV ventricle refractory period.  Before we added the CP, we 
increased the basic cycle length of the biventricular pacing by approximately 50 
% above the level needed to pace both ventricles during AF.  Then we added the 
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CP beat at a delay of 250 ms.  Next, we progressively shortened this time delay 
until we observed by echocardiography that there was no subsequent LV 
mechanical contraction resulting from the CP.  Finally we extended the basic 
biventricular pacing rates to be close to sinus rates such that the rates of 
ventricular contractions were similar. 
     Finally, we applied CRT alone at a rate close to sinus rate (step 5).  We were 
able to apply CRT at this rate because we selectively simulated the 
parasympathetic nerves that innervate the AV node (pulses = 20 Hz. 0.1ms, 10 
mA). 
     We systematically collected the data at the end of each pacing mode as 
described above with a current echocardiograph system (Vivid 7, GE 
Healthcare).  For each measurement, five consecutive cardiac cycles were 
acquired and all images were stored on optical disk for further analysis. LV 
contractility was quantified by 1) LV ejection fraction, 2) stroke volume and 3) the 
peak value of the circumferential global strain (ε-peak).  LV ejection fraction (EF) 
was computed from standard apical views by using the Simpson biplane method.  
Circumferential global strain curve was computed by averaging the 6 segmental 
circumferential ε curves derived from 2D short axis view (basal segment) by 
using speckle tracking analysis (EchoPac GE Healthcare).  For all ε analysis, 
end-diastole was chosen as the reference time-point for each cardiac cycle.  
Peak ε had been defined as strain curve, when it reached its maximum value 
during the cardiac cycle. The time for each of the 6 segments to reach their peak 
strain was expressed in terms of the percentage of the RR interval for that 
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particular cardiac cycle because of the wide range of RR intervals for these 
pacing paradigms in this study. The measure of LV dyssynchrony is the standard 
deviation of percentage of the time to peak circumferential ε for each cardiac 
cycle.  For example, if all 6 segmental peak ε occurred exactly at the same time 
in the cardiac cycle the standard deviation would be zero. Conversely if the 6 
segmental peaks of ε were reached over a wide range of time, the LV 
dyssynchrony would be large.  Diastolic period was defined as the time duration 
of the Doppler early diastolic filling velocity profile (E) during atrial fibrillation and 
as the sum of E and atrial velocity waves multiplied by the duration during sinus 
rhythm. This measurement also was normalized to the RR interval for each 
cardiac cycle. Again, because CP does not cause contractions, this electrical 
activation of the ventricles was not considered in the above calculations.  
     Normally distributed continuous variables were expressed as a mean ± SD. 
To compare numerical data between two or several groups, paired and unpaired 
student test or analysis of variance was used as appropriate. Two-tailed P-values 
<0.05 were considered statistically significant. Analysis was performed using 
StatView® software (Version 5.0 for Windows®, SAS institute Inc., Cary, NC, 
USA). 
4.3 Results 
     The average LV dyssynchrony during sinus rhythm was approximately 7±2% 
(Figure 11A).  The induction of simulated LBBB by right ventricular pacing (RV) 
increased LV dyssynchrony to an average of 19±3% (p<0.0001 vs. SR).  The 
application of biventricular pacing (CRT) dramatically reduced this LV 
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dyssynchrony virtually back to the level of sinus rhythm (SD=8± 3 %).  In three 
animals we stimulated selectively the parasympathetic nerves innervating the AV 
node (CRT-VS).  This is analogous to those LBBB patients with concurrent AF in 
which their ventricular rate can be controlled by pharmacological agents such 
that the CRT could be applied at a more appropriate rate.  In this case, the LV 
dyssynchrony was similar to that during sinus rhythm (SD = 7 ± 2%).  Finally, 
when we applied an additional paced beat to only the right ventricle (CRT+CP), 
LV dyssynchrony did not increase (SD = 8 ± 3%).  Note the average 
corresponding QRS durations were measure during these echocardiographs and 
are shown for all 5 steps of this study.   
     During sinus rhythm, the average peak global strain was -12 ± 2% (Figure 
12B) when the VRMC was 128±17cpm.  With the induction of acute AF and rapid 
RV pacing (VRMC=219±39cpm), the peak global strain decreased to -4 ± 2%.  
The application of CRT during acute AF slightly improved peak global strain (-6 ± 
3%) despite the rapid VRMC (232 ± 15cpm).  The reduction in VRMC (103 ± 
14cpm) during CRT-VS further improved the strain until it approached that found 
in sinus rhythm (-11 ± 3%).  Finally, the addition of the CP beat (CRT+CP) 
increased peak global strain to a level greater than that found during sinus 
rhythm (-16 ± 2%). Note that the VRMC was 116 ± 17cpm during this pacing 
paradigm.  
     During sinus rhythm, the average diastolic duration was 40 ± 6% of each 
cardiac cycle (Figures 11C).  The tachycardia of acute AF plus LV dyssynchrony 
of RV pacing decreased this percentage duration to 30 ± 9% (p = 0.02 vs. SR).  
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The reduction in LV dyssynchrony and rapid pacing of CRT did not improve the 
percentage of diastolic duration (33 ± 8%).  The reduction in rate by CRT-VS also 
did not prolong the diastolic duration in relation to the cardiac cycle length (27 ± 
3%).  Finally, the CRT+CP pacing paradigm did increase this percentage (48 ± 
6%). 
     Finally, the LV ejection fraction dramatically decreased from 52 ± 4% to 19 ± 
6% (p<0.0001, Figure 11 D) as the result of the tachycardia and LV 
dyssynchrony.  The resynchronization of the rapid contractions did improve the 
LVEF slightly (25 ± 6%).  Also the reduction in the ventricular rate by 
parasympathetic nerve stimulation also improved LVEF (25 ± 4%).  However, 
once again the addition of CP to CRT (CRT+CP), improved the LVEF (51 ± 10%) 
to that of sinus rhythm despite the continual acute AF. 
 
 
 
 
 
 
 
 
  Figure 11: Changes in LV dyssynchrony (A), global strain (B), diastolic duration (C) 
and LV ejection fraction (D) during the 5 stages of this study. (*) for p<0.05 vs. 
baseline, (†) for p<0.05 vs. RV pacing, (‡) for p<0.05 vs. CRT, (¥) for p<0.05 vs. CRT-
VS. 
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4.4 Discussion 
      The major finding of this study is that if atrial fibrillation should occur with 
heart failure patients that are utilizing CRT, the beneficial effects of CRT could 
continue if the biventricular pacemaker had the capabilities of applying coupled 
pacing.  Normally if the atrial rate exceeds a prescribed limit, the atrial tracking by 
biventricular pacemakers would stop and the pacemaker would mode switch to 
VVIR. This new pacing mode results in a less effective pacing therapy than 
would occur if CRT was being applied.  In the present study, we demonstrated 
that CRT+CP is capable of slowing supraventicular activation of the heart by half 
in a similar manner as coupled pacing does when the ventricular conductive 
system is intact.  As a consequence, if AF should occur, the CRT could 
continually be applied at an optimal rate.  Additionally, CP added to the CRT 
provides positive inotropic effect.  This increase of contractility and diastolic filling 
provided by CRT+CP should also be considered as an option for therapy in non 
responder patients with sinus rhythm in which CRT alone has not improved their 
cardiac function as it does in others (responders). 
     In patients with severe heart failure (NYHA III-IV), depressed LV function 
(EF<35%) and a wide QRS complex (QRS>120ms), the beneficial effects of CRT 
have been documented with improvement of symptoms [1-8] and prognosis [8]. 
Reduced mechanical dyssynchrony with CRT decreases wall stress, mitral 
regurgitation volume [2, 4, and 18] and increases stroke volume [18-21], LV dP/dt 
[17 and 22] and ultimately leads to LV reverse remodeling [1-2, 4, and 8]. In most 
cases, the beneficial effect of CRT seems effective in both sinus rhythm and AF 
 51
patients [23].  However, efficient CRT delivery during either paroxysmal or 
chronic AF required a pharmacological control of ventricular rate because CRT 
devices which use an atrial tracking mode are set at an upper tracking limit to 
avoid a rapid ventricular tachycardia. In drug-refractory AF patients, AV nodal 
ablation with permanent pacemaker implantation or pulmonary vein ablation may 
be needed [9]. An alternative therapy to these procedures would be a simple 
modification of the CRT algorithm, i.e., CRT+CP, which consists of delivering a 
supplemental beat after the biventricular pacing.  
     Published results showed that CP reduces the mechanical rate of contraction 
during acute AF [11-13].  Coupled pacing differs from paired stimulation in that it 
uses the spontaneous ventricular depolarization as the first of the 2 electrical 
activations [14]. This intrinsic activation determines when the second of the 
paired stimuli is applied.  Since the second beat travel retrogradely into the AV 
node and blocks approximately half of the supraventricular activation of the heart, 
coupled pacing results in a rate of ventricular contraction approximately half that 
which occurs prior to the application of stimulation. These techniques had been 
successively used to reduce ventricular rate during ventricular tachycardia [24], 
atrial tachycardia and fibrillation [11-13]. Consistent to our previous findings, we 
found that CRT+CP also permitted us to apply the biventricular pacing at half the 
rate that CRT alone that would have to be applied during AF.  This negative 
chronotropic effect of CRT+CP resulted in an increased in the diastolic period for 
improved LV filling and presumably the coronary flow. In addition to the 
subsequent beneficial impact of a slower heart rate, the addition of the CP beat 
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appears to increase the diastolic/systolic time ratio (Figures 11C).  These results 
suggest CRT+CP not only increase the intracellular calcium ions supply but may 
also affect the subsequent re-sequestering of this ion.  
     In addition to the negative chronotropic effect of CRT+CP, this new pacing 
paradigm (CRT+CP) resulted in a positive inotropic effect similar to coupled 
pacing.  This increase in contractility has been termed “postextrasystolic 
potentiation”. The mechanism for this potentiated response is the increased 
release of calcium [14].  In 1965, Ross and Braunwald [25-26] termed this 
positive inotropic effect “electro-augmentation” because it was induced by 
electrical pacing rather than pharmacological agents.  Paired stimulation, first 
proposed as a heart failure therapy more than 50 years ago, increases systolic 
function of the heart [14 and 26-27]. The effects of paired stimulation are 
generally achieved by applying two closely paced stimuli to the right ventricle. 
     However, when compared to intrinsic activation of the ventricles, continual 
right ventricular pacing can be detrimental because of the dyssynchrony 
produced by such a pacing paradigm [17].  Prior application of paired stimulation 
has been shown to increase MVO2 proportionally to its positive inotropic effect 
[25].  In addition to the dyssynchrony, paired stimulation normally is applied at a 
rate equal or greater than the intrinsic rate.  In contrast, when CP is applied, the 
contractile rate is one half the intrinsic activation rates and CP does not induce 
dyssynchrony.  As a result, we did not observe a marked increase in MVO2 
during the application of CP [12]. In the present study, we did not measure the 
 53
oxygen consumption.  However, CRT+CP like CP reduces the contractile rate 
and does not cause dyssynchrony as does paired pacing. 
     Since stimuli are applied prematurely, there is a risk that these stimuli could 
induce ventricular tachycardia, which might lead to ventricular fibrillation. 
However, extending the delay of coupled stimuli (less prematurely) still maintains 
improved cardiac function [13].  In addition, Mischke et al [24] had recently 
demonstrated that in the worst clinical situation, paired ventricular stimulation can 
be safely delivered during ventricular tachycardia in patients with predominantly 
ischemic LV dysfunction (17/22 ischemic, LVEF=38 ± 14%).  Additionally, we 
have never observed any ventricular arrhythmia with a premature stimulation 
appropriately delivered as described.  However, if ventricular tachycardia were 
induced, the episode could be quickly terminated with a pacemaker/internal 
cardiac defibrillator system.  Importantly, in symptomatic heart failure patients 
with severe LV dysfunction requiring an Implanted Cardiac Defibrillator (ICD), CP 
could be assessed with a high degree of safety.  
     In acute dyssynchronized dysfunctional heart with concurrent AF, CRT+CP 
slows the ventricular contractile rate and provides a greater increase in 
myocardial contractility and the diastolic filling compared to CRT alone in which 
the ventricular rate can be controlled by parasympathetic nerve stimulation.  The 
addition of a coupled beat permits the CRT to be applied at a slower and more 
appropriate rate for optimal cardiac function. 
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Chapter V 
Simulation of Flow in the Great cardiac Vein and the Use of Sensors for 
Monitoring Flow for Use in Cardiac Pacing Monitoring 
 
5.1 Introduction 
     In order to effectively use pacing paradigms such as coupled pacing, it is 
essential that the pacing device have some measure of the response of the heart 
to this pacing other than just sensing intrinsic electrical activations.  In the past, 
and T. Bennett et al [1] and D. Steinhaus et al [2], had been involved in the 
development of implantable hemodynamic monitoring systems for the 
management of heart failure patients. Bennett and his colleagues at the 
Medtronic Corporation had developed the Chronicle ® System which is an 
implantable homodynamic monitor (IHM). Their IHM system comprised a monitor 
(which included pressure sensing circuits and a means for storing continuous 
pressure trends, pressure sensors, and a pressure data storage monitoring 
device. These implantable pressure sensors had been sealed and included a 
means for indicating changes in the right ventricular pressure [1].  Medtronic’s 
Chronicle ® System had been designed to be implanted in the same manner in 
which pacemakers are implanted. Bennett al concluded from their IHM studies 
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that their implantable hemodynamic monitor could be permanently placed in 
heart failure patients.  
     Since the right ventricular pacing lead enters the heart via the cephalic vein, 
one could measure blood flow returning to the heart via 2 pressure sensors on 
this lead at the level of the superior vena cava.  Although measurement would 
only represent a portion of the cardiac output, this measurement should reflect 
changes in cardiac output.  In those cases where left ventricular pacing is 
needed such as CRT, one implants a pacing lead into coronary sinus. On this 
second lead, 2 additional pressure sensors could be attached to measure 
coronary sinus flow via differential pressure. I have developed 2 different mock 
circulatory systems, designated as Mock I and II Circulatory Circuit which 
provides a means by which the flow profiles which exist in both the great cardiac 
vein (GCV) and the Superior Vena Cava (SVC) structures can be simulated in 
order to confirm that the differential pressure obtained in this system is 
representative of flow. 
     Historically, The Bernoulli Equation had been considered to be a statement of 
the conservation of energy principle which is appropriate for the flow of fluids.  
The Bernoulli equation [3] is shown below (the original form): 
• V2  + gh + (p/ρ) = constant  Equation (1) 
Where: 
o (V) represents the fluid velocity at a point on a 
streamline; 
o (g) Represents the acceleration due to gravity,  
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o (h) Represents the height of the point above a reference 
plane,  
o (p) Represents the pressure at the point,  
o (ρ) Represents the density of the fluid at all points in the 
fluid. 
And the fluid must be: 
• Must be incompressible even though the pressure is varying 
and the density must remain constant. 
• The streamline cannot enter the boundary layer 
o A boundary layer is defined as that fluid layer that is 
adjacent to the bounding surface 
• Turbulent flow occurs when the fluid particles move in a 
random fashion in the (x), (y), and (z)-directions in a blood 
vessel  
• And there are no viscous forces present [4]. 
     Since the pressure sensors may move from the boundary layer and the 
streamline as the heart contracts. And since blood flowing through the native 
great cardiac vein (GCV) is turbulent and viscous in nature, the simulation does 
take these limitations into account as will be discussed later.  I can theoretically 
assume that the flow as produced in our mock circulatory circuit does follow the 
differential pressure as measured by the two Millar pressure sensors. And that 
the Bernoulli equation is not applicable for our simulation of flow profiles in the 
GVC since the fluid flowing through the mock circuit has a high viscosity and is 
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undoubtedly turbulent. 
     This mock circulatory circuit is simulating the pulsatile flow of the great cardiac 
vein through a conduit and should also be addressed in order to realistically 
model flow profiles through this cardiac vein. DA McDonald discussed the 
relationship that exists between the pressure gradient to the derivative of 
pressure with respect to time [5]. If the distance between two points which is 
represented as (Δz) is very small, this pressure gradient can be expressed after 
being differentiated as: 
• (dp/dz) = (dp/dt)* (dt/dz)    Equation (2)  
where: 
o (dp/dz) represents the “space coefficient” with respect to 
time. [5] 
And if (c) is used to represent the velocity of the “pulse wave” which develops, 
then equation (2) can now be written as: 
• (-dp/dz) = (1/c) (dp’dt) Equation (3) 
Since the flow rate is dependent on the pressure gradient, it is also “dependent 
on the rate of change of the pulse pressure” [5].  This time derivative calculation 
of flow had been with the assumption that blood as a fluid had no viscosity and 
traveled through a conduit (blood vessel) without any type of distortion which has 
been found not to be the case. That is blood is a highly viscous fluid and blood 
flow through a blood vessel with a lot of variation since it is a pulsatile flow [5]. 
And as discussed by Mcdonald [5], the viscous nature of blood results in a 
dampening of its “amplitude” and decreases its velocity.  Thus the pressure 
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gradient as represented by Equation (3) is “directly related to flow” as stated in 
the McDonald text [5]. And the factors which “modify” this pressure gradient 
should be taken into account these factors, e.g. “wave reflections”, non-linear 
effects, distensibility and viscosity effects, in order to more accurately represent 
pulsatile flow in blood vessels. 
     There are some limitations of my mock circulatory circuit such the fluid used 
does not have the same viscosity as blood and the fluid flow is somewhat 
Newtonian whereas blood is somewhat non-Newtonian in nature.  However, it 
should be stated that this mock circulatory circuit (Figure 12) does approximate 
the flow rate through a conduit or vessel, taking into account the flow analyses 
done by Womersley and Bernoulli [5]. Also the vessels as represented by the 
conduit have to be curved and this curvature changes with each contraction 
since the great cardiac vein is in fact highly curved in nature. Thus, the mock 
circulatory circuit simulates the flow profiles in the great cardiac vein do 
approximate the pulsatile flow of blood which is related to differential pressure. 
    
5.2 Simulation of the Great Cardiac Vein (Mock Circulatory Circuit) 
1. Simulate the flow profiles of the Great Cardiac Vein (GVC) in a mock 
circulatory circuit which will simulate flow profile changes of the native GVC. 
2. Perform post-sampling techniques on the raw data obtained from 
mechanical model to determine the extent of processing required to measure flow 
via differential pressure using standard acceptable signal processing techniques. 
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3. Confirm that preliminary flow profile data obtained using this mock 
circulatory testing system follows the differential pressure measurements obtained 
from the pair of Millar pressure sensors in a linear fashion. 
4. Re-design mock circulatory circuit as necessary to improve simulation 
results if aim 1 is feasible and based on 1st phase of our acute animal studies. 
5. The results of this part of my dissertation work can be used as a basis for 
others to modify implantable pressure sensors which can be attached to pre-
existing pacing leads to optimally provide a means for adjusting the pacing 
regimens in both CRT and CRT+CP pacing paradigms. 
5.3 Methods 
5.3.1 Bench Testing Phase I: I used the mock circulatory circuit for simulating 
flow profiles in the great cardiac vein, as discussed during my Candidacy.  This 
mock circulatory circuit (Figure 12) is comprised of the following components: a 
reservoir which represents blood flow returning from the capillary beds; a 
peristaltic pump mechanism (A Harvard Systems Ventilator).   The movement of 
the shaft of this pump was used to change the curvature of the tubing used to 
emulate the movement of the GCV during ventricular contraction as well as 
provide a pulsatile flow.  A flow probe; a screw clamp which represents the 
thoracic cavity’s pressure change; a flow meter; two Millar pressure transducers, 
for obtaining a differential pressure; and a DATAQ Data Acquisition System for 
digitalizing all analog signals obtained for performing post sampling analysis.  All 
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data collection had been obtained using the DATAQ D1-720 Hardware and 
WINDAQ acquisition software. 
     Prior to the collection differential pressure and flow data, all mock circulatory 
circuit components had been calibrated, i.e. the flow meter and both Millar 
transducer boxes both calibrated and balanced. Separate experimental trials of 
flow data were collected over a period of 5 minutes for each individual run.  The 
sample rate was set at 3000 (actual computer sample frequency had been 
2999.625) for the three recording channels with a moving average value-set to a 
value of 50. DATAQ’s moving average algorithm involves the use of a smoothing 
factor. More specifically, this algorithm allows one to specify the number of actual 
waveform data points or samples that the moving average will span. It 
accomplishes a moving average by taking two or more of these data points from 
the acquired waveform, adding them, dividing their sum by the total number of 
data points added, replacing the first data point of the waveform with the average 
just computed, and repeating the steps with the second, third, and so on data 
points until the end of the data is reached. This results in the generated 
waveform to consist of averaged data which has the equivalent number of data 
points as the original waveform had.  It should also be noted that the distance 
between the two Millar sensors had been measured to have a length of 3.0 
centimeters. And the distance between the end of the 2nd Millar sensor and flow 
probe had been set at 5 cm. 
     Based upon the work of Cohen [6] and the preliminary results of D. Wallick et 
al, I completed the development of a mechanical mock circulatory system that 
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generated both flow and pressures similar to that measured in the great cardiac 
vein of dogs.  This was achieved by means of changing the stroke volume of a 
pulsatile pump, changing the curvature of the tubing (“GCV”) and altering the 
outflow resistance of this system.  Since the great cardiac vein is located around 
the circumference of the base of the left ventricle, the vessel undergoes a 
significant amount of movement during normal contraction. I collected initial 
simulated GVC Flow Profiles to determine that that the flow produced by the 
Mock Circuit does follow differential pressures obtained by the two Millar 
pressure sensors. I then confirmed that the flows produced by the mock 
circulatory circuit are representative of the approximate baseline flow 
measurement for the GVC, as determined by Cohen et al [6], i.e. 42.9 +/- 4.1 
ml/min.   
2nd Phase of Bench Testing Phase: In two separate experiments I used 
markedly different construction of leads in which the pressure sensors could be 
mounted.  In the first series (Mock I Circuit as shown in Figure 13), I used 
sensors that had been mounted on a very flexible catheter system.  In the 
second series of experiments (Mock II Circuit as shown in Figure 14), I used a 
stiffer catheter system in to ensure that I had effectively changed the arc of the 
great vein system and substituted in a Gilson Minipuls 2 Peristaltic Pump in place 
of the A Harvard Systems Ventilator in order to remove any negative pressures 
that had been observed in my Mock I Circuit.  The purpose of the second series 
of experiments is to determine how pressure measurements would have to be 
obtained in order to accurately reflect the flow within the simulated vessel.  This 
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was the worst-case scenario, in which pressures measurements would be 
affected by the movement of the heart.  In the first two series of experiments, I 
used water as a medium to measure blood flow.  In the second group of 
experiments I used a medium that would better emulate the viscosity of blood 
(ethylene glycol). These experiments would be used as a basis for re-designing 
my Mock Circulatory Circuit to obtain more accurate and precise GVC flow 
profiles. Once the appropriate modifications were made to my mock circuit, 
simulated flow profiles had been collected as well as performing both post 
sampling and statistical analysis on this phase of simulated flow profile data 
(Table II) to optimize the results.  
Mechanical simulation of blood flow in the great cardiac vein:  Using a 
pulsatile pump, a Windkessel capacitor, and a flexible tube that is distorted in a 
similar manner as occurs to the cardiac vein during ventricular contraction, I have 
simulated the pressure and flow characteristics of blood in the great cardiac vein 
of a dog’s heart using the Mock Circulatory Circuits as illustrated in Figure 13-14.  
The mock circulatory testing system as shown in this Figure 12 comprised the 
following components: a reservoir (A) which will include a roller pump; a 
peristaltic pump or roller pump (B) which is representative of the torsional motion 
of the heart caused by the pressure sensors moving within the coronary vessels; 
a differential torque mechanism (C) which is representative of the torsional force 
changes of the heart itself; a flow probe (D); a screw clamp (E) which represents 
the thoracic cavity’s pressure change; a flow meter (F); two pressure transducers 
(G) and (H), respectively, for obtaining a differential pressure as illustrated by (I); 
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and Data Acquisition System (DAQ) represented as (J). With 2 Millar pressure 
sensors for measuring cardiac vein flow and an extracorporeal flow probe for 
comparison, I was able to determine that measurements of differential pressure 
will adequately measure flow in this system (refer to Table II). 
5.3.2. Experimental methods/tools (Mock I and II Circuits): 
1. DATAQ® Software with WINDAQ/XL add-on software 
2. (2) Millar pressures sensors 
3. Acquisition period for each trial (5 minutes) 
4. Origin® plotting software 
Table I: Experimental protocol for Data Acquisition 
Channel Number (#) Channel Designates 
#1 Pressures from 1st pressure sensor 
#2 Pressures from 2nd pressure sensor 
#3 Flow being recorded 
#4 Smoothed data from 1st pressure sensor 
#5 Smoothed data from 2nd pressure sensor 
#6 Channel # 4 – Channel #5 
#7 Smoothed data from channel #3 
 
 
Pressure 
Transducer # 1 (G)
Pressure Transducer 
# 2 (H) 
Peristaltic 
Pump (B) 
Reservoir (A) 
Differential 
Torque 
Flow 
Probe (D) 
Screw 
Clamp (E) 
Differential Pressure (I)
Flow Meter (F)
DAQ System (J) 
 
Figure 12: Schematic of components for simulation of the flow 
in the great cardiac vein (GVC). 
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Figure 13: Photograph of the Mock I Circulatory Circuit. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Photograph of the Mock II Circulatory Circuit. 
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Figure 15: Photograph which shows an actual recording of differential pressures as 
recorded by 2 Millar Pressure Transducers for two recording channels using the Mock II 
Circuit and DATAQ software. 
 
5.4 Results (Mock II Circuit) 
     Origins plotting software for data which obtained for 20 seconds using the 
Mock II Circuit is shown in Figure 16.  From this origin plot, it can be concluded 
that flow does follow differential pressure as measured by a pair of Millar 
pressure sensors.  DATAQ® software with WINDAQ/XL, which is a software add-
on to WinDaq (DATAQ® Instrument), had been used to as a post-sampling 
analysis tool for establishing the foundation for future acute studies.  Note that 
only results obtained from the Mock II circuit (Figure 16) will be presented. As 
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was discussed earlier, I had made changes to the 1st mock circulatory circuit to 
develop a more realistic simulation of flow profile in the GVC, e.g. used a stiffer 
catheter system in order to ensure that the position of the catheter and therefore 
the pressure sensor moved as the simulated contraction occurred. The plots as 
shown in (Figure 16) had been obtained using the Origin plotting software; 
illustrates the relationship between the changes in pressure vs. flow.  Several 
experimental runs using the Mock II Circuit (Figure 14) had been performed and 
the plots of some of these trials had been presented in these figures. Figure 32 
as shown is a photograph illustrating an actual recording of differential pressures 
as recorded by 2 Millar Pressure Transducers for two recording channels using 
the Mock II Circuit and DATAQ software. Table III illustrates the statistical 
analysis for two of the experimental trial runs using the Mock II circuit. 
 
Table II Illustrates the Statistical Analysis for Two Trial Runs 
 
 
DATE 
PERFORMED, 
TRIAL #,  
X VARIABLE Y VARIABLE NUMBER 
OF DATA 
POINTS  
ST. DEV P VALUE R VALUE 
8-20-07, #3 Change in 
Pressure 
(mmHg) 
Flow (ml/m) 20181 14.057 < 0.0001 .74156 
9-2-07, #15 Change in 
Pressure 
(mmHg) 
Flow (ml/m) 20095 14.529 < 0.0001 .79073 
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Figure 16: Change in Pressure vs. Flow for Trial #3 on 8-20-07. Note the 
blue line represents the linear fit performed. 
5.5 Conclusions 
     Our prior results [7-9] demonstrate that an effective treatment of AF and heart 
failure results in an increase in the ratio of external cardiac work to myocardial 
energy consumption, i.e. an increase in myocardial efficiency [8].  This ratio can 
be increased if the cardiac work is preserved or increased while the therapy 
decreases the total amount of energy used by the heart. In contrast, the 
efficiency of the heart diminishes if the heart uses energy that does not lead to 
external work. One such example occurs during AF when the rapid ventricular 
activations result in isovolumic contractions that result in no ejection of blood 
from the heart, thus no external work. Prevention of partial isovolumic 
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contractions would stop the use of energy that results in no external work, thus 
increasing the efficiency of the heart. It has been previously demonstrated that 
CP prevents these non-ejecting beats and increases the heart’s mechanical 
efficiency [7-8].  In order to obtain these values, one would normally have to 
measure ventricular pressures and volumes as well as myocardial oxygen 
consumption.  There are now pacemaker systems that can measure right 
ventricular pressure [1]. Our work indicates that CP does not significantly alter 
mean systemic pressure.  However, the measurement of both changes in and 
absolute ventricular volumes values can be quite difficult to obtain. Thus, the 
measurement of external cardiac work would be challenging in the clinical 
setting.  Next, the durability of oxygen sensors and their ability to measure 
coronary sinus oxygen content is questionable.  In addition, in order to measure 
myocardial oxygen consumption, one has to measure coronary blood flow as well 
as the extraction of oxygen.  However, our previous results indicate that changes 
in coronary blood flow parallels the changes in myocardial oxygen consumption 
[8]. That is, the extraction of oxygen from the heart remains relatively constant 
despite changes in metabolic demand.  Therefore, the short-term changes in 
coronary blood flow generally indicate corresponding changes in myocardial 
oxygen consumption, a measure of total energy used by the heart.  
     Based on both the bench trials and the previous work, a modified ratio of a 
portion of cardiac output to coronary sinus blood flow appears as the most 
feasible cardiac parameter that could be used as a control system to provide 
optimal pacing. Since it is standard practice to secure a ventricular pacing lead to 
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the right ventricular apex via the cephalic vein for ventricular pacing, one could 
measure blood flow returning to the heart via a proximal flow sensor on this lead 
in the superior vena cava.  Although measurement would represent only a portion 
of the cardiac output, it would be a simple representative measurement of cardiac 
output.  In those cases where left ventricular pacing is needed, one could implant 
a pacing lead into the coronary sinus, now a standard clinical practice for 
biventricular pacing. On this second lead, an additional flow sensor could be 
attached to measure coronary sinus flow.  Also 4 of these sensors could be 
incorporated onto the lead that enters the great cardiac vein (see Figure 17).  By 
periodically determining the ratio of “cardiac output” to coronary sinus flow, one 
could determine if this index of cardiac efficiency changes.  Then based on the 
changes in this index, the pacing algorithm could be adjusted.  In order to validate 
that this ratio is the best cardiac parameter to use in our control system, we could 
compare this proposed index to other standard measurements such as average 
ventricular rate and right ventricular pressure. 
 
5.6 Future Work 
 
     There is the potential for using implantable pressure sensors as shown in 
(Figure 17) for optimizing either CRT and or our novel pacing paradigm 
(CRT+CP).  Future acute animal studies could involve comparing the responses 
of predetermined sensors, e.g. implantable pressure sensors in the GVC and 
SVC veins (Figures 17) which provide a means for measuring cardiac output and 
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coronary sinus blood flow.  As flow is increased in the great cardiac vein or the 
superior vena cava vein, the differential pressure (GCV1 – GCV2) or (SVC1 – 
SVC2) would change the balance of the Wheatstone bridge circuit configuration. 
If the changes are similar the balance would remain the same. But if flow is 
increased proportionally at a greater value in the GVC than in the SVC, there 
would now be a change which reflects that the heart’s efficiency is decreasing. 
Thus the appropriate changes could be made to optimize cardiac pacing in heart 
failure patients. 
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Figure 17: A diagram of our proposed new biventricular pacemaker .with our 
new ventricular pacing leads. Note the 2 Xs on the right ventricular lead.  They 
indicate the 2 pressure sensors located in the superior vena cava that would 
measure a portion of venous return “cardiac output”. Similarly note the 2 Xs on 
the left ventricular pacing leads. These sensors are located in the great cardiac 
vein and would be used to measure coronary blood flow. 
     In order test our hypotheses and compare the sensors, we could adjust the 
time delay for CP and CP+CRT in order to obtain the maximal efficiency index 
under conditions similar to those described in previous work [4]. We could use 
this 
value of efficiency as a set point and then use a negative feedback control 
system to monitor deviations from the set point with our sensors.  Our control 
system could then adjust the values toward the predetermined set point values 
for the purpose of varying the pacing parameters within clinically acceptable 
ranges.  Most likely, we would change the time delay of the stimuli and/or apply 
the stimuli intermittently as needed. Post-sampling techniques could then be 
used to determine the optimal set points. 
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